SAMSN1 and Miyoshi myopathy: Neither the upregulation of SAMSN1 by transgenic overexpression, nor the downregulation of SAMSN1 by CRISPR‐mediated genome editing, affected the growth of metastatic tumors of human MM cell lines within the BM of immunodeficient NSG mice.